Thursday, February 17, 2011

GSK trimming Triangle jobs



GlaxoSmithKline is eliminating an undisclosed number of jobs in Research Triangle Park as it prunes its work force to reflect reductions in research and development spending that it made last year.

The job cuts are in the company's Neurosciences Medicine Development Center, which is primarily based in RTP.

Fewer than 50 R&D positions are being cut across the U.S., and less than half of those are in RTP, said Melinda Stubbee, a company spokeswoman.


The majority of the cuts are occurring at various clinical trial sites in the U.S., but not at the company's R&D facilities in the Philadelphia area.

The company declined to give an exact number because it will depend on how many people are redeployed to other areas of the company.

London-based GSK employs about 4,000 people in RTP, where it has its U.S. headquarters. It also has employees in Zebulon, where it operates a manufacturing facility.

The company has been slashing costs and restructuring its business as generic rivals have hurt sales of its blockbuster drugs.

Between 2007 and 2010 the company cut about 22,000 jobs worldwide, but also added jobs in growth areas - emerging markets, consumer products and vaccines.

It now employs about 96,500 people.

In February 2010, the company announced that it was withdrawing from some areas of neurosciences research in order to focus on areas that it felt had more promise.

GSK also announced last year that it would drastically reduce its real estate footprint in the Triangle over the next 18 months as it relocates 1,000 employees to the company's Moore Drive campus in RTP.

GSK has reported losses in two of its last three quarters.

Its earnings have been hurt by a $3.4 billion charge to cover legal costs stemming from its controversial diabetes drug Avandia and a federal investigation into the company's sales and promotional practices.

GSK announced earlier this month that it plans to buy back as much as $3.23 billion worth of its shares. The company also promised to return to shareholders the proceeds from the planned sale of its slowest-selling consumer brands.






By

NEHA JAIN

      

   

     



            
AeroSoft Corp Indore| Aviation B2B Services | Best SEO  in Indore |www.aerosoft.in                                                                                                                











No comments:

Post a Comment